




P R E L I M I N A R Y P R O G R A M

	TUESDAY DECEMBER 10	WEDNESDAY DECEMBER 11	THURSDAY DECEMBER 12	FRIDAY DECEMBER 13
08:00 10:00		SESSION 1: Basic Science of HIV Latency	SESSION 4: Immunology of HIV Persistence	SESSION 7: Human Studies
10:00 10:30		COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
10:30 12:30		SESSION 2: Virology of HIV Persistence	SESSION 5: In vitro & Animal Model Studies of HIV Persistence	SESSION 8: Antibody & Immune based therapies
12:30 14:00		LUNCH	LUNCH	12:30 - 13:00 CLOSING REMARKS
14:00 16:00		13:00 - 15:00 Satellite Session Translating Science	SESSION 3: Drug Discovery Development & Pharmacology	SESSION 6: Cell & Gene Therapies
16:00 17:00		15:30 - 17:30 Satellite Session NIMH Funded Studies	Highlighted Short Talks I	Highlighted Short Talks II
17:00 19:30		18:30 - 19:30 OPENING SESSION	Poster Session I	Poster Session II
19:30 22:30		WELCOME DINNER		



DECEMBER 10
01:00PM - 03:00PM
SATELLITE WORKSHOP

Satellite Workshop - Translating Science: A Training Workshop to Support Communicating Cure Science

This is geared toward early stage investigators, community partners, and anyone interested in growing their ability to share research across different stakeholders. The workshop will provide tools and templates for sharing research with lay audiences and utilize interactive training methods to improve communication and engagement skills.

Jessica Salzwedel (New York, United States)
Mike Franke (The Düsseldorf Patient, Velen, Germany)

DECEMBER 10
03:30PM - 05:30PM
SATELLITE WORKSHOP

Satellite Workshop - Research outcomes from NIMH funded Studies

Leveraging Host Cellular Pathways for Targeting HIV CNS/Myeloid Reservoirs

Co-Chairs:

Mario Stevenson, University of Miami, Miami, FL
Kiera Clayton, University of Massachusetts, Worcester, MA

03:30PM - 03:35PM

Welcome Remarks and Meeting Goals
Jeymohan Joseph, NIMH, Rockville, MD

03:35PM - 03:55PM

Metabolic strategies to eliminate CNS Myeloid Viral Reservoirs
Eliseo Eugenin, University of Texas, Galveston, TX

03:55PM - 04:10PM

Strategies Signaling Strategies for Depletion of HIV reservoir by activation of ISR Signaling
Guochun Jiang, University of North Carolina, Chapel Hill, NC

04:10PM - 04:25PM

Targeting HIV Myeloid Reservoirs in the CNS by IAP and TREM1 Inhibition
Grant Campbell, University of South Dakota, Vermillion, SD

04:25PM - 04:40PM

Targeting the HIV-1 Reservoir in Myeloid Cells using the SECH approach
Jin Wang, Methodist Hospital Research Institute, Houston, TX

04:40PM - 04:55PM


CSF1R inhibition depletes brain macrophages and reduces brain virus burden in SIV-infected macaques
Woong-Ki Kim, Tulane University, New Orleans, LA

04:55PM - 05:10PM

Repurposing BCL-2 and Jak 1/2 inhibitors for targeting myeloid reservoirs
Boghuma Kabisen Titanji, Emory University, Atlanta, GA

05:10PM - 05:30PM

Research Gaps and Future Research Areas Discussion
Mario Stevenson and Kiera Clayton



DECEMBER 10

06:30PM

OPENING LECTURES

Opening Lectures

Overall cure landscape from the NIH perspective

Carl Dieffenbach (Bethesda, United States)

Community Voice: Living on ART and Why a Cure is Necessary

Antoinette Jones (Atlanta, United States)

DECEMBER 11

08:00AM - 10:00AM

SESSION 1:

Session 1: Basic Science of HIV Persistence

1.0 Cellular activation, gene expression, and proviral reactivation

Tokameh Mahmoudi (Rotterdam, The Netherlands)

Oral Presentations

1.1 - 0003 Longitudinal analysis in early treated individuals reveals alteration in the HIV-1 integration site landscape and composition of the inducible reservoir

Tine Struyve (Ghent, Belgium)

1.2 - 0005 Blood and tissue HIV-1 reservoirs display cellular plasticity and lack of compartmentalization in virally suppressed people

Marion Pardons (Ghent, Belgium)

1.3 - 0008 Persistence of HIV genomes in bacteria-specific CD4+ T cells during ART

Armando Espinosa Ortiz (Montréal, Canada)

1.4 - 0011 Identification of the cellular transcription factor KLF16 (Krüppel-like factor 16) as a new HIV-1 silencing factor

Maryam Bendoumou (Brussels, Belgium)

1.5 - 0018 Intact Proviruses Persist in Expressed Genes in People with HIV-1 on Long-term ART

Sean Patro (Frederick, MD, United States)

1.6 - 0016 HIV-1 Antisense Transcripts are frequent in FOXP3-negative Treg-like cells expressing markers of persistence in vivo during acute HIV-1 infection

Matthew Hale (Silver Spring, MD, United States)

DECEMBER 11

10:30AM - 12:30PM

SESSION 2:

Session 2: Virology of HIV Persistence

2.0 Title TBA

Joel Blankson (Baltimore, United States)

Oral Presentations


2.1 - 0004 Lenacapavir impairs gag proteins expression by HIV-infected cells

Clayton Faua (Strasbourg, France)

2.2 - 0005 Role of HIV integration site on clonal expansion of infected cells and maintenance of latency in vivo

Virender Pal (New York, United States)





DECEMBER 11
02:00PM - 04:00PM
SESSION 3:

2.3 – 00078 Detection of HIV-1 antisense transcripts in donor samples before and during ART

Adam Capoferri (Frederick, United States)

2.4 – 00143 Selective export of HIV mRNAs is regulated by compartmentalized interactions with Sam68, PTB and m6A RNA methylation in reactivated latently infected T-cells

Frederick Kizito (University heights, United States)

2.5 – 00074 Propagation of HIV reservoir clones reveals functional heterogeneity, suggesting diverse mechanisms of persistence

Isabella Ferreira (New York, United States)

2.6 – 00158 Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV

Alexander Pasternak (Amsterdam, Netherlands)

Session 3: Drug Discovery & Development, Pharmacology, Novel approaches

2.0 TACK

Bonnie Howell (West Point, United States)

Oral Presentations

3.1- 00145 Exploring novel HIV Tat inhibitors

Sonia Jablonski (Jupiter, United States)

3.2 – 00080 New PKC Modulator Latency Reversing Agents for depleting persistent HIV reservoirs

Matthew D. Marsden (Irvine, United States)

3.3 – 00093 RasGRP1 agonists induce cyclin T1 translation to reverse HIV-1 latency in primary CD4+ T cells

Uri Mbonye (Cleveland, United States)

3.4 – 00150 Unbiased Genome-Wide CRISPR Screens in Primary Human CD4+ T Cells Identify Novel Proviral and Anti-viral HIV Host Factors

Ujjwal Rathore (San Francisco, United States)


3.5 – 00053 Monovalent SMAC mimetics enhance proliferation of HIV-specific CD8 T cells

Kiho Tanaka (Melbourne, Australia)

3.6 – 00159 Clinical and virologic outcomes of an art interruption in treated controllers and non-controllers

Michael Peluso (San Francisco, United States)





DECEMBER 11

04:00PM - 05:00PM

HIGHLIGHTED SHORT TALKS OF
INTEREST I:

Highlighted Short Talks of Interest I

ST1.0 Block and Lock strategy for HIV cure
Susana Valente (Jupiter, United States)

Oral Presentations

ST1.1 - 00095 Single cell transcriptomic characterization of the gastrointestinal HIV reservoir
Edward Browne (Chapel Hill, United States)

ST1.2 - 00105 Characterization of the molecular mechanisms involved in the CD8+ T cell-mediated non-cytolytic silencing of HIV-1 transcription
Antoine Dutilleul (Brussels, Belgium)

ST1.3 - 00171 Venetoclax decreases intact proviral DNA frequency in SIV-infected, ART-suppressed Rhesus Macaques
Sydney Bergstresser (Atlanta, United States)

ST1.4 - 00008 Persistent HIV-1 unintegrated linear DNA can integrate and lead to viral replication after integrase inhibitor treatment removal
Matthieu Maisch (Paris, France)

Session 4: Immunology of HIV Persistence

4.0 Understanding the landscape of lymph node HIV reservoirs during ART through single cell analysis
Michael Betts (Pennsylvania, United States)

Oral Presentations

4.1 - 00057 Tissue resident memory programs of intestinal CD4+ and CD8+ T cells facilitate HIV-1 persistence
Yulong Wei (New Haven, United States)

4.2 - 00027 Secondary cytotoxicity of memory CD8+ T cells targeting autologous HIV during treated chronic infection is associated with suppression of provirus and of recrudescence viremia
David Collins (Cambridge, United States)

4.3 - 00124 HIV infection induces T cell quiescence, leading to proviral latency
Saba Valadkhan (Cleveland, United States)

4.4 - 00091 Molecular Drivers of HIV-Induced Immune Modulation and CD8+ T Cell Dysfunction in Lymph Node Follicles during ART-Suppressed Subtype C Infection
Zaza Ndhlovu (Durban, South Africa)

4.5 - 00020 Control of HIV infection is associated with enhanced CD8 T cell functionality during consecutive analytical treatment interruptions
Gabriel Duette (Westmead, Australia)


4.6 - 00114 Transcriptomic profile of gut T follicular helper cells during persistent HIV infection
Francesca Cossarini (New York, United States)

DECEMBER 12

08:00AM - 10:00AM

SESSION 4:





DECEMBER 12
10:30AM - 12:30PM
SESSION 5:

Session 5: In Vitro and Animal Model Studies of HIV Persistence

5.0 Title TBA

Mirko Paiardini (Atlanta, United States)

Oral Presentations

5.1 – 00136 Plasma SIVmac239M clonotypes in rebound viremia correspond to those induced by AZD5582 during ART
Ann Chahroudi, Atlanta USA

5.2 – 00120 Well-seeded reservoirs in gut are associated with tertiary lymphoid organs and stress response activation
Ramon Lorenzo-Redondo (Chicago, United States)

5.3 – 00106 Macrophage-tropic TF SHIV D infected NHP model of reservoir persistence, decay and pathogenesis on suppressive anti-retroviral therapy
Suvadip Mallick (Philadelphia, United States)

5.4 – 00148 Targeting Wnt/ β -catenin signaling pathway during latency reversal in ART-suppressed SIV-infected rhesus macaques
Maud Mavigner (Atlanta, United States)

5.5 – 00117 HIV-Tocky system in primary CD4+T cells joined with transcriptomic and epigenomic analysis to discover mechanism involves in the establishment of latency during acute infection
Wajihah Sakhor (Kumamoto, Japan)

5.6 – 00133 Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques
Yuntao Wu (Manassas, United States)

DECEMBER 12
02:00PM - 04:00PM
SESSION 6:

Session 6: Cell & Gene Therapies

5.0 CRISPr

John Tisdale (Bethesda, United States)

Oral Presentations


6.1 – 00142 Durable Viral Load Remission in SHIV-infected Macaques after Vectored Delivery of Monoclonal Antibodies
Jose Martinez-Navio (Miami, United States)

6.2 – 00049 Multivalent CAR T Cell Therapy Shows Superior Potency in Controlling HIV Escape and Replication in BLT Humanized Mice
Federica Severi (Philadelphia, United States)

6.3 – 00019 AAV Delivery of the CCR5-blocking monoclonal antibody Leronlimab yields long-term expression and ART-free remission from SHIV viremia
Helen Wu (Beaverton, United States)

6.4 – 00112 Overcoming immune responses directed toward AAV-delivered bNAbs
Michael Kuipa (Atlanta, United States)





DECEMBER 12
04:00PM - 05:00PM
HIGHLIGHTED SHORT TALKS OF
INTEREST II:

6.5 – 00173 A single-infusion of CCR5 modified stem-like CD4 T cells to limit HIV/SIV persistence during ART and promote control of viremia upon ATI
Ashish Sharma (Atlanta, United States)

6.6 – 00176 CAR/CCR9 T cell immunotherapy shows promise in localization of SIV-specific CAR T cells to the gastrointestinal tract of rhesus macaques
Pam Skinner (Oakdale, United States)

Highlighted Short talks of interest II

ST2.0 Distinct features of HIV persistence in children
Katherine Ruiz De Luzuriaga (Worcester, United States)

Oral Presentations

ST2.1 – 00087 A Novel HIV-1 Immune Evasion Strategy: How Softer HIV-1 Infected cells Preferentially Resist Cytotoxic T Lymphocytes (CTLs)
Louise Leyre (New York, United States)

ST2.2 – 00065 Models and correlates of intact and defective HIV DNA decay in Kenyan children over 8 years of ART
Daniel Reeves (Seattle, United States)

ST2.3 – 00128 Targeting Myeloid Reservoirs Harboring Replication-Competent HIV
Jin Wang (Houston, United States)

ST2.4 – 00035 Bach2 controls seeding of HIV reservoirs in memory CD4+ T cells
Liang Shan (St. Louis, United States)

Session 7: Human Studies

7.0 Diversity in clinical studies: identifying and overcoming barriers
Esper Kallás (Sao Paulo, Brazil)

Oral Presentations

7.1 – 00113 Safety and PD-1 receptor occupancy with low dose Nivolumab in adults living with HIV on antiretroviral therapy: NIVO-LD
James McMahon (Melbourne, Australia)


7.2 – 00123 Peptide-induced apoptosis of latently infected cells and reduction of the HIV reservoir in people living with HIV: preliminary results of a clinical trial
Ricardo Sobhie Diaz (Sao Paulo, Brazil)

7.3 – 00050 Profound reduction of HIV-1 reservoir cells over three decades of antiretroviral therapy started in early infancy
Katherine Ruiz De Luzuriaga (Worcester, United States)

7.4 – 00119 Anatomic Distribution of HIV-infected clones in tissues after long-term antiretroviral therapy
Frank Maldarelli (Frederick, United States)

DECEMBER 13
08:00AM - 10:00AM
SESSION 7:





DECEMBER 13
10:30AM - 12:30AM
SESSION 8:

7.5 – 0009 Postmortem analyses of the central nervous system in individuals with HIV demonstrate that infection of microglia contributes to inflammatory pathways despite viral suppression.

Marieke Nühn (Utrecht, Netherlands)

7.6 – 0052 The Tuberculosis Associated Microenvironment Reduces CD8+ T-Cell Control of HIV at the Site of the Coinfection

Samantha Cronin (Sydney, Australia)

Session 8: Antibody & Immune based Therapies

Development of multispecific antibodies for HIV

John Mascola (Western, United States)

Oral Presentations

8.1 – 0022 Short-term Combination Immunotherapy with bNAbs and CCR5 Blockade Mediates ART-Free Viral Control in Infant Rhesus Macaques

Gabriela Webb (Beaverton, United States)

8.2 – 0072 Early intervention with an indoline CD4-mimetic compound that sensitizes HIV-1-infected cells to ADCC favors post-treatment HIV control in humanized mice

Li Zhu (New Heaven, Unites States)

8.3 – 0088 Epitope-Driven Effector Functions of Broadly Neutralizing Antibodies Across Diverse HIV Isolates: Insights for Next-Generation Therapeutics

Chia Jung Li (Cambridge, Massachusetts, United States)

8.4 – 0081 IL-15/IL-15RA therapy enhances control of viral rebound in SIV-infected macaques

Sakthivel Govindaraj (Atlanta, United States)

8.5 – 0015 Changes in the composition of HIV-1 reservoir of PWH on ART and dasatinib

Mario Manzanares Torrijos (Majadahonda, Spain)

8.6 – 0097 Increased HIV-1 proviral reactivation and reservoir size in people with HIV on anticancer treatment

Laura Perez-Blazquez (Madrid, Spain)

